The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 132, Issue 2, 2012, Pages 355-363

  Candelaria Quintana, Dulcinea ^a   Dayao, Zoneddy R ^a   Royce, Melanie E ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Bisphosphonates; Bone loss; Bone metastases; Breast cancer; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; GOSERELIN; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ZOLEDRONIC ACID;

ACUTE PHASE REACTION; ANTINEOPLASTIC ACTIVITY; ANTIRESORPTIVE THERAPY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER STAGING; CANCER TREATMENT INDUCED BONE LOSS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OUTCOME ASSESSMENT; OVARY INSUFFICIENCY; OVERALL SURVIVAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SOLID TUMOR; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84859101303     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1800-z     Document Type: Review

References (80)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60:277-300
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
3. Mundy GR (2002) Metastasis tobone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593
4. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588-1594
5. Saad F (2008) New research findings onzoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev 34: 183-192
6. Weinfurt KP, Li Y, Castel LD et al (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579-584 (Pubitemid 40613323)
7. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474
8. Xgeva (denosumab) [package insert] (2010) Amgen Inc., Thousand Oaks
9. Zometa (zoledronic acid) [package insert] (2011) Novartis Pharmaceuticals Corporation, East Hanover
10. Mhaskar R, Redzepovic J, Wheatley K et al. (2010) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev CD003188
11. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342 (Pubitemid 40852708)
12. Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978 (Pubitemid 30413179)
13. Reclast (zoledronic acid) [package insert] (2010) Novartis Pharmaceuticals Corporation, East Hanover
14. Brufsky AM, Bosserman LD, Caradonna RR et al (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85
15. Eidtmann H, de Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZOFAST study. Ann Oncol 21:2188-2194
16. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849
17. Llombart A, Frassoldati A, Paija O et al. (2009) Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Poster presented at ASCO 2009 breast cancer symposium, San Francisco, 9-10 Oct 2009 (Abstr 213)
18. Shapiro CL, Halabi S, Hars V et al (2011) Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 47:683-689
19. Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882
20. Anastasilakis AD, Toulis KA, Goulis DG et al (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41:721-729
21. Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132-5139
22. NationalOsteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington
23. Eastell R, Adams JE, Coleman RE et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051-1057
24. Sverrisdottir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE (2004) Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694-3699 (Pubitemid 41095208)
25. Vehmanen L, Elomaa I, Blomqvist C, Saarto T (2006) Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 24:675-680 (Pubitemid 46630433)
26. Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73-82
27. Fuleihan GE, Salamoun M, Mourad YA et al (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90:3209-3214 (Pubitemid 41014277)
28. Vehmanen L, Saarto T, Elomaa I et al (2001) Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37:2373-2378 (Pubitemid 33097473)
29. Delmas PD, Balena R, Confravreux E et al (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955-962 (Pubitemid 27106277)
30. Hines SL, Mincey BA, Sloan JA et al (2009) Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27: 1047-1053
31. Saarto T, Vehmanen L, Elomaa I et al (2001) The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 84:1047-1051 (Pubitemid 32448500)
32. Confavreux CB, Fontana A, Guastalla JP et al (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41:346-352 (Pubitemid 47199159)
33. Greenspan SL, Brufsky A, Lembersky BC et al (2008) Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26:2644-2652
34. Van Poznak C, Hannon RA, Mackey JR et al (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967-975
35. Singh S, Cuzick J, Edwards R et al (2007) Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the international breast cancer intervention study (IBIS-II) [abstract]. Breast Cancer Res Treat 106(suppl 1):S9 (Abstr 28)
36. Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342
37. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)
38. Hershman DL, McMahon DJ, Crew KD et al (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26:4739-4745
39. Hershman DL, McMahon DJ, Crew KD et al (2010) Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 95:559-566
40. Hines SL, Mincey B, Dentchev T et al (2009) Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 117:603-609
41. Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744 (Pubitemid 37238631)
42. Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321
43. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082-1090 (Pubitemid 30127670)
44. Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399-1405 (Pubitemid 37185286)
45. Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133-1137 (Pubitemid 38496803)
46. Kristensen B, Ejlertsen B, Groenvold M et al (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246:67-74 (Pubitemid 29327354)
47. Paterson AH, Powles TJ, Kanis JA et al (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65 (Pubitemid 23059975)
48. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88:701-707 (Pubitemid 32831138)
49. Stopeck A, Martin M, Ritchie D et al. (2010) Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Poster presented at the 33rd annual San Antonio breast cancer symposium, San Antonio, 8-12 Dec 2010 (Abstr P6-14-01)
50. Winter MC, Holen I, Coleman RE (2008) Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453-475
51. Neville-Webbe HL, Coleman RE, Holen I (2010) Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 102:1010-1017
52. Canon JR, Roudier M, Bryant R et al (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25:119-129
53. Aft R, Naughton M, Trinkaus K et al (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11:421-428
54. Coleman RE, Marshall H, Cameron D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. doi: 10.1056/NEJMoa1105195 55.
55. Coleman RE, Winter MC, Cameron D et al (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099-1105
56. Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
57. Lin AY, Park JW, Scott J et al (2008) Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]. J Clin Oncol 26(suppl):20s (Abstr 559)
58. Rack B, Juckstock J, Genss EM et al (2010) Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 30:1807-1813
59. Solomayer EF, Gebauer G, Hirnle P et al (2008) Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [poster]. Presented at: 31st annual San Antonio breast cancer symposium. San Antonio, TX, pp 10-14 (Abstr 2048)
60. Zaghloul MS, Boutrus R, El-Hossieny H et al (2010) A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15:382-389
61. Zarogoulidis K, Boutsikou E, Zarogoulidis P et al (2009) The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125:1705-1709
62. Diel IJ, Jaschke A, Solomayer EF et al (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19:2007-2011
63. Powles T, Paterson A, McCloskey E et al (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8:R13
64. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C (2004) Ten-year follow-up of arandomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656 (Pubitemid 39563937)
65. Chlebowski RT, Chen Z, Cauley JA et al (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582-3590
66. Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577-3581
67. Newcomb PA, Trentham-Dietz A, Hampton JM (2010) Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799-802
68. Thomas DM, Skubitz KM (2009) Giant cell tumour of bone. Curr Opin Oncol 21:338-344
69. Mystakidou K, Katsouda E, Parpa E et al (2005) Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22:195-201 (Pubitemid 41003454)
70. Vincenzi B, Santini D, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144-151 (Pubitemid 40354834)
71. Coleman R, Bundred N, de Boer R et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Poster presented at the 32nd annual San Antonio breast cancer symposium, San Antonio, 9-13 Dec 2009 (Abstr 4082)
72. Gnant M, Mlineritsch B, Stoeger H et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641
73. Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826-836 (Pubitemid 351768801)
74. Mauri D, Valachis A, Polyzos IP et al (2009) Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 116:433-439
75. Ripamonti CI, Maniezzo M, Campa T et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137-145
76. Badros A, Terpos E, Katodritou E et al (2008) Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 26:5904-5909
77. Amgen provides update on status of prolia(TM) (denosumab) biologics license application (BLA) submitted to the U.S. Food and Drug Administration (FDA) [press release]. Amgen Inc., Thousand Oaks, CA, October 19, 2009. Available at: http://wwwext.amgen.com/media/media-pr-detail.jsp?year= 2009&releaseID=1343288. Accessed 18 August 2011
78. US Department of Health and Human Services US Food and Drug Administration BLA Approval Letter June 1, 2010-BL 125320/0. US Department of Health and Human Services, Silver Spring, MD, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2010/125320s0000ltr.pdf. Accessed 18 August 2011
79. Peterson MC, Jang G, Kim W et al. (2006) Selection of a phase 3 dose regimen for denosumab based on pharmacokinetic (PK), pharmacodynamic (PD), and safety data from multiple subcutaneous (SC) dosing regimens in breast cancer patients (Pts) with bone metastases (BM). Poster presented at the 42nd annual meeting of the American Society of Clinical Oncology, Atlanta, 2-6 June 2006 (Abstr 3086)
80. Miller PD, Bolognese MA, Lewiecki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222-229